Ainos, Inc. Stock price

Equities

AIMD

US00902F3038

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.14 USD -3.39% Intraday chart for Ainos, Inc. -10.24% -44.39%
Sales 2022 3.52M Sales 2023 122K Capitalization 8.32M
Net income 2022 -14M Net income 2023 -13M EV / Sales 2022 3.36 x
Net cash position 2022 585K Net Debt 2023 3.81M EV / Sales 2023 99.3 x
P/E ratio 2022
-0.6 x
P/E ratio 2023
-0.61 x
Employees 46
Yield 2022 *
-
Yield 2023
-
Free-Float 44.39%
More Fundamentals * Assessed data
Dynamic Chart
Ainos, Inc. Appoints Christopher Hsin-Liang Lee as Chief Financial Officer CI
Ainos, Inc. Announces Resignation of Meng-Lin Sung, the Chief Financial Officer CI
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street MT
Top Premarket Decliners MT
Ainos, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Top Premarket Gainers MT
Ainos Submits Clinical Hold Complete Response to US FDA to Address Issues in Phase 2 Veldona Trial MT
Ainos, Inc. Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase Ii Trial of Its Veldona Formulation Against Mild Covid-19 Symptoms CI
Ainos, Inc. Enters into Five-Year Product Development Agreement with Taiwan Carbon Nano Technology Corporation CI
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected MT
Ainos Regains Compliance With Nasdaq Listing Rule MT
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-Development Powered by Ai Nose, Accelerating the Digitalization of Smell CI
Ainos, Inc. Announces Resignation of John Junyong Lee as Chief Legal Counsel and Corporate Secretary CI
Ainos Says Three Clinical Studies for Veldona Show 'Positive' Data MT
Ainos, Inc. Announces Positive Data Reports from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA CI
More news
1 day-3.39%
1 week-10.24%
Current month+11.76%
1 month+29.43%
3 months-44.39%
6 months-62.31%
Current year-44.39%
More quotes
1 week
1.12
Extreme 1.1201
1.33
1 month
0.86
Extreme 0.8619
3.10
Current year
0.79
Extreme 0.79
4.29
1 year
0.79
Extreme 0.79
6.10
3 years
0.79
Extreme 0.79
356.25
5 years
0.79
Extreme 0.79
356.25
10 years
0.79
Extreme 0.79
356.25
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 21-04-14
Chief Operating Officer 55 21-07-31
Sales & Marketing - -
Members of the board TitleAgeSince
Director/Board Member 70 21-04-14
Director/Board Member 66 22-06-14
Director/Board Member 47 21-04-14
More insiders
Date Price Change Volume
24-03-28 1.14 -3.39% 110 690
24-03-27 1.18 -4.07% 72,124
24-03-26 1.23 -3.91% 47,432
24-03-25 1.28 -1.54% 47,846
24-03-22 1.3 +2.36% 159,158

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Ainos, Inc. is a diversified healthcare company, which is focused on the development of point-of-care testing (POCT), low-dose VELDONA interferon therapeutics and synthetic Ribonucleic Acid (RNA)-driven preventative medicine. The Company's products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. VELDONA Pet is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. Its pipeline of products, which are under development, includes VELDONA human drugs, VOC POCT-Ainos Flora, VOC platform-NISD co-development, VOC POCT-Ainos Pen, VOC POCT-CHS430 and Synthetic RNA. VELDONA human drugs are the high-priority programs include oral warts for human immunodeficiency virus seropositive patients, common cold, influenza, Sjogrens syndrome and treatment for mild COVID-19 symptoms.
More about the company
  1. Stock
  2. Equities
  3. Stock Ainos, Inc. - Nasdaq